Switch theme
Sign up to access all valuation multiples
AcuCort AB is an innovative biotechnology company that identifies, develops and commercializes smart drugs that meet the patient’s needs for a user-friendly and effective treatment.
2006
2
LTM Revenue $0.3M
LTM EBITDA -$1.8M
$16.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AcuCort has a last 12-month revenue (LTM) of $0.3M and a last 12-month EBITDA of -$1.8M.
In the most recent fiscal year, AcuCort achieved revenue of $0.1M and an EBITDA of -$1.4M.
AcuCort expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AcuCort valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.3M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | $0.2M | XXX | $0.8M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 1143% | XXX | XXX | XXX |
| EBITDA | -$1.8M | XXX | -$1.4M | XXX | XXX | XXX |
| EBITDA Margin | -628% | XXX | -2009% | XXX | XXX | XXX |
| EBIT | -$2.3M | XXX | -$1.8M | XXX | XXX | XXX |
| EBIT Margin | -808% | XXX | -2576% | XXX | XXX | XXX |
| Net Profit | -$2.3M | XXX | -$1.8M | XXX | XXX | XXX |
| Net Margin | -808% | XXX | -2577% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AcuCort's stock price is SEK 1 (or $0).
AcuCort has current market cap of SEK 199M (or $20.5M), and EV of SEK 161M (or $16.6M).
See AcuCort trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16.6M | $20.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AcuCort has market cap of $20.5M and EV of $16.6M.
AcuCort's trades at 238.3x EV/Revenue multiple, and -11.9x EV/EBITDA.
Equity research analysts estimate AcuCort's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AcuCort has a P/E ratio of -8.9x.
See valuation multiples for AcuCort and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20.5M | XXX | $20.5M | XXX | XXX | XXX |
| EV (current) | $16.6M | XXX | $16.6M | XXX | XXX | XXX |
| EV/Revenue | 58.1x | XXX | 238.3x | XXX | XXX | XXX |
| EV/EBITDA | -9.3x | XXX | -11.9x | XXX | XXX | XXX |
| EV/EBIT | -7.2x | XXX | -9.3x | XXX | XXX | XXX |
| EV/Gross Profit | 82.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.9x | XXX | -11.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAcuCort's last 12 month revenue growth is 493%
AcuCort's revenue per employee in the last FY averaged $35K, while opex per employee averaged $1.3M for the same period.
AcuCort's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AcuCort's rule of X is 604% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AcuCort and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 493% | XXX | 584% | XXX | XXX | XXX |
| EBITDA Margin | -628% | XXX | -2009% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -1516% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 604% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $35K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3719% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AcuCort acquired XXX companies to date.
Last acquisition by AcuCort was XXXXXXXX, XXXXX XXXXX XXXXXX . AcuCort acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AcuCort founded? | AcuCort was founded in 2006. |
| Where is AcuCort headquartered? | AcuCort is headquartered in Sweden. |
| How many employees does AcuCort have? | As of today, AcuCort has 2 employees. |
| Is AcuCort publicy listed? | Yes, AcuCort is a public company listed on SAT. |
| What is the stock symbol of AcuCort? | AcuCort trades under ACUC ticker. |
| When did AcuCort go public? | AcuCort went public in 2017. |
| Who are competitors of AcuCort? | Similar companies to AcuCort include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of AcuCort? | AcuCort's current market cap is $20.5M |
| What is the current revenue of AcuCort? | AcuCort's last 12 months revenue is $0.3M. |
| What is the current revenue growth of AcuCort? | AcuCort revenue growth (NTM/LTM) is 493%. |
| What is the current EV/Revenue multiple of AcuCort? | Current revenue multiple of AcuCort is 58.1x. |
| Is AcuCort profitable? | Yes, AcuCort is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AcuCort? | AcuCort's last 12 months EBITDA is -$1.8M. |
| What is AcuCort's EBITDA margin? | AcuCort's last 12 months EBITDA margin is -628%. |
| What is the current EV/EBITDA multiple of AcuCort? | Current EBITDA multiple of AcuCort is -9.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
